Ghassan Abou-Alfa, MD
Medical Oncology · New York, NYNPI 1134190168
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Eisai Inc. at 44.5% of the total. Reporting peaked in 2020 at $281,152 and has fallen 94.9% since, to $14,266 in 2025. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $2349.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$367K
- Ipsen Biopharmaceuticals, Inc$82K
- AbbVie$58K
- AstraZeneca$54K
- Incyte Corporation$42K
- Astrazeneca UK Limited$37K
- plus $185K from 22 others
Across 170 payments — averaging $11,948 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.4M
- QED Therapeutics, Inc.$161K
- Agios Pharmaceuticals, Inc.$137K
- Incyte Corporation$88K
- Exelixis Inc.$52K
- E.r. Squibb & Sons, L.L.C.$48K
- plus $162K from 8 others
What the payments were for
- Consulting fees$432,64652%
- Speaking & faculty fees$255,68131%
- Travel & lodging$127,71915%
- Food & beverage$5,7181%
- Education$50%
- Charitable contribution$3,0000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 128 | $366,897 |
| Ipsen Biopharmaceuticals, Inc | 36 | $82,023 |
| AbbVie | 26 | $57,871 |
| AstraZeneca | 41 | $53,765 |
| Incyte Corporation | 18 | $42,162 |
| Astrazeneca UK Limited | 21 | $37,365 |
| Agios Pharmaceuticals, Inc. | 6 | $24,066 |
| Ipsen Innovation | 3 | $19,967 |
| F. Hoffmann-la Roche AG | 6 | $18,567 |
| Merck | 15 | $15,631 |
| Sirtex Medical Inc | 5 | $13,661 |
| Exelixis Inc. | 7 | $13,245 |
| E.r. Squibb & Sons, L.L.C. | 3 | $11,470 |
| Servier Pharmaceuticals LLC | 4 | $10,458 |
| Genentech, Inc. | 4 | $9,149 |
| Beigene, Ltd. | 1 | $6,728 |
| Taiho Oncology, Inc. | 2 | $6,000 |
| Insmed, Inc. | 1 | $5,950 |
| Genentech USA, Inc. | 7 | $4,960 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $4,875 |
| Eisai CO., LTD. | 1 | $4,750 |
| Bristol Myers Squibb | 3 | $4,627 |
| Biocompatibles, Inc. | 2 | $4,445 |
| Servier Bioinnovation | 1 | $4,125 |
| Lilly USA, LLC | 1 | $875 |
| Halozyme Inc | 1 | $600 |
| Astrazeneca AB | 5 | $453 |
| Puma Biotechnology, Inc. | 2 | $83 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$371,065
- ONIVYDE$77,049
- IMFINZI$51,663
- TIBSOVO$38,559
- TECENTRIQ$30,553
- PEMAZYRE$17,400
- SIR-Spheres Microspheres$13,661
- Cabometyx$13,245
- Avastin$8,134
- OPDIVO$6,750
- TRUSELTIQ$4,875
- SOMATULINE DEPOT$4,750
- Abraxane$4,627
- THERASPHERE-BIO$4,400
- Non-Covered Product$1,870
- MK-3655$1,000
- CYRAMZA$875
How this compares
$824,769 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 20 | $495,620 |
| CreonLipase/Protease/Amylase | 27 | $82,146 |
| ZenpepLipase/Protease/Amylase | 11 | $22,924 |
| Enoxaparin Sodium | 15 | $3,688 |
| Oxycodone Hcl | 41 | $572 |
| Ondansetron Hcl | 35 | $541 |
| Pantoprazole Sodium | 22 | $253 |
| Spironolactone | 24 | $229 |
| Furosemide | 30 | $215 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $134 |
| Tamsulosin Hcl | 11 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $13,245 | $495,62020 claims |
| AbbVieCreon | $57,871 | $82,14627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
- David SolitNew York$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.